Cyclosporine-Induced Alopecia: A Case Report, FDA Adverse Event Reporting System Analysis and Literature Assessment

This case report describes a 29-month-old boy with severe aplastic anemia who developed alopecia during cyclosporine (CsA) therapy, a known side effect typically associated with hypertrichosis. The alopecia, affecting the scalp, eyebrows, and eyelashes, did not improve with topical minoxidil but resolved after discontinuing CsA. An analysis of the FDA Adverse Event Reporting System (FAERS) from 2004 to 2023 identified 118 cases of CsA-induced alopecia, suggesting a potential correlation. The study underscores the importance of clinical awareness and monitoring of this paradoxical reaction in patients on CsA, despite limitations such as the lack of a cutaneous biopsy.